OM:CAMXPharmaceuticals
Camurus (OM:CAMX) Valuation in Focus After Positive Phase 1b Results for Monthly GLP-1 Candidate
Camurus (OM:CAMX) just released positive topline results from a Phase 1b trial testing its monthly GLP-1 candidate, CAM2056, against weekly semaglutide in people living with overweight or obesity. This outcome could have key implications for both the company and patients.
See our latest analysis for Camurus.
Camurus has captured investors’ attention lately, as excitement around the CAM2056 results helped drive a 3.5% share price gain in the last day and an impressive 18.1% return over the...